A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC

INTRODUCTION: RET rearrangements define a distinct molecular subset of NSCLC. The multikinase inhibitor ponatinib reveals potent activity in preclinical models of RET-rearranged NSCLC. METHODS: In this single-arm, multicenter, phase II trial, we evaluated the clinical activity of ponatinib in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Gainor, Justin F., Gadgeel, Shirish, Ou, Sai-Hong I., Yeap, Beow, Otterson, Gregory A., Shaw, Alice T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474450/
https://www.ncbi.nlm.nih.gov/pubmed/34589941
http://dx.doi.org/10.1016/j.jtocrr.2020.100045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474450/
https://www.ncbi.nlm.nih.gov/pubmed/34589941
http://dx.doi.org/10.1016/j.jtocrr.2020.100045

Ejemplares similares